These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 37247161)

  • 1. Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC).
    Mustafa M; Abbas K; Alam M; Ahmad W; Moinuddin ; Usmani N; Siddiqui SA; Habib S
    Mol Cell Biochem; 2024 Apr; 479(4):895-913. PubMed ID: 37247161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
    Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
    BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer.
    Sayed-Ahmed MM; Hafez MM; Al-Shabanah OA; Al-Rejaie SS; Aleisa AM; Al-Yahya AA; Alsheikh A; Al Diab AI; Al-Akeely MH
    Tumori; 2013; 99(4):545-54. PubMed ID: 24326846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer.
    Kumari L; Mishra L; Patel P; Sharma N; Gupta GD; Kurmi BD
    J Drug Target; 2023 Dec; 31(9):889-907. PubMed ID: 37539789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple negative breast cancer: new therapeutic approaches and BRCA status.
    Guney Eskiler G; Cecener G; Egeli U; Tunca B
    APMIS; 2018 May; 126(5):371-379. PubMed ID: 29696717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
    Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M;
    Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
    Okuma HS; Yonemori K
    Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple negative breast cancer: looking for the missing link between biology and treatments.
    Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
    Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biology and Management of Patients With Triple-Negative Breast Cancer.
    Sharma P
    Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
    Qin JJ; Yan L; Zhang J; Zhang WD
    J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.
    Mahfoudh W; Bettaieb I; Ghedira R; Snoussi K; Bouzid N; Klayech Z; Gabbouj S; Remadi Y; Hassen E; Bouaouina N; Zakhama A
    J Transl Med; 2019 Apr; 17(1):123. PubMed ID: 30975216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
    Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
    Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.
    De Santis F; Romero-Cordoba SL; Castagnoli L; Volpari T; Faraci S; Fucà G; Tagliabue E; De Braud F; Pupa SM; Di Nicola M
    Cell Oncol (Dordr); 2022 Apr; 45(2):257-274. PubMed ID: 35357654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.
    Zhao H; Li D; Zhang B; Qi Y; Diao Y; Zhen Y; Shu X
    Molecules; 2017 Dec; 22(12):. PubMed ID: 29261144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
    Papadimitriou M; Mountzios G; Papadimitriou CA
    Cancer Treat Rev; 2018 Jun; 67():34-44. PubMed ID: 29753961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulated Gab1 signalling in triple negative breast cancer.
    Bongartz H; Mehwald N; Seiß EA; Schumertl T; Naß N; Dittrich A
    Cell Commun Signal; 2024 Mar; 22(1):161. PubMed ID: 38448989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.
    Geenen JJJ; Linn SC; Beijnen JH; Schellens JHM
    Clin Pharmacokinet; 2018 Apr; 57(4):427-437. PubMed ID: 29063517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
    Anders CK; Abramson V; Tan T; Dent R
    Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies.
    Medina MA; Oza G; Sharma A; Arriaga LG; Hernández Hernández JM; Rotello VM; Ramirez JT
    Int J Environ Res Public Health; 2020 Mar; 17(6):. PubMed ID: 32245065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast Cancer: Current Molecular Therapeutic Targets and New Players.
    Nagini S
    Anticancer Agents Med Chem; 2017; 17(2):152-163. PubMed ID: 27137076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.